Why the study?
Does disopyramide compared to lignocaine affect cardiac dimensions and left ventricular function in normal volunteers?
Does disopyramide compared to lignocaine affect cardiac dimensions and left ventricular function in normal volunteers?
Disopyramide demonstrates a significant negative inotropic effect compared to lignocaine at therapeutic plasma concentrations in normal volunteers.
Disopyramide's negative inotropy in normals suggests caution in LV impairment; challenges prior safety assumptions and leaves open effects in patients.
1 The cardiac effects of disopyramide (D) and lignocaine (L) were measured and compared in normal volunteers (D n=4; L n=3) following the establishment of a series of three steady-state drug plasma concentrations spanning the therapeutic range (1.5-5 micrograms base ml-1). 2 During control and steady-state periods multiple measurements were made of heart rate, blood pressure, drug concentrations and echocardiographic measurement of cardiac dimensions and estimated left ventricular function. 3 No change in heart size or estimated function occurred with L except for a small increase in estimated cardiac output (+0.5 1 min-1) secondary to a small rise in heart rate (maximum +7 beats min-1). Blood pressure rose slightly (maximum +11 mmHg). 4 D caused an increase in heart size, marked at end systole (+0.63 cm), and a decrease in echo indices of ventricular function (25-33%). These changes were related to plasma drug concentration but were not reflected in cardiac output estimation since heart rate rose (+15 beats min-1). Blood pressure also rose (+10 mmHg). 5 Significant differences were shown between D and L at similar plasma drug concentrations. The negative inotropic effect of D may be greater than previously suggested and clinically important.
No takes yet. Share an insight, caveat, or question.
Martin et al. (1980) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: